Abstract
Erlotinib is an epidermal growth factor inhibitor. It is used for refractory, local invasion or metastasized non-small cell lung cancer. Erlotinib doesn’t cause severe systemic side effects like cytotoxic drugs. But it causes toxic side effects in skin. Acneiform eruption is the most common side effects related to erlotinib using. It is thought that balance is disturbed between differentiation and maturation of keratinocytes, ecrine and sebaceous gland cells and hair follicle cells in etiology. Topical metronidazole, clindamycin, topical salicylic acid and tetracycline can be used in treatment. In case of severe acneiform eruption dose of erlotinib may be reduced or treatment of erlotinib may be delayed. Our case was 67 years old male presented with acneiform eruption on his face after erlotinib treatment for non-small cell lung cancer. We decide to report this case because early diagnosis and treatment of skin lesions related to erlotinib treatment is important for patient compliance with erlotinib treatment.
References
- Schalock PC, Zug KA. Acneiform reaction to erlotinib. Dermatitis 2007; 18: 230
- Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
- Ong CK, Tan WC, Chan LC; Razak MA. Cutaneous Side-Effects of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (TKI) In the Treatment of Lung Cancer: Description and Its Management. Med J Malaysia 2012; 67: 222-3. Journagan S, Obadiah J. An acneiform eruption due to erlotinib: Prognostic implications and management. J Am Acad Dermatol 2006; 54: 358-60.
- Bovenschen HJ, Alkemade JA, Erlotinib-induced dermatologic side-effects. Int. J. Dermatol 2009; 48: 326-8.
- Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33.
- Hidalgo M, Siu LL, Nemunaitis J. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-79.
- Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric antiepidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002; 138: 129-31.
Abstract
Erlotinib bir epidermal büyüme faktörü reseptörü inhibitörüdür. Dirençli, lokal yayılmış ya da metastaz yapmış küçük hücreli dışı akciğer kanserlerinde kullanılır. Erlotinib sitotoksik ilaçlar gibi ciddi sistemik yan etkiler oluşturmaz. Fakat ciltte toksik yan etkiler yapabilir. Erlotinib kullanımına bağlı en sık gelişen cilt lezyonu akneiform erüpsiyondur. Etyolojide keratinositler, ekrin ve sebase bez hücreleri ve saç folikül hücrelerindeki farklılaşma ve olgunlaşmasındaki dengenin bozulduğu düşünülmektedir. Tedavide topikal metronidazol, topikal klindamisin, topikal salisilik asit ve tetrasiklin kullanılabilir. Çok ağır akneiform erüpsiyonlarda erlotinibin dozu azaltılabilir ya da tedavi ertelenebilir. Olgumuz küçük hücreli dışı akciğer kanseri için erlotinib tedavisi sonrasında yüzünde akneiform erüpsiyon gelişen 67 yaşında erkek hastaydı. Hastaya lokal klindamisin fosfat ve benzoil peroksit karışımı tedavisi verildi. Erlotinib tedavisine bağlı gelişen cilt lezyonlarının erken tanınması ve tedavi edilmesi hastanın erlotinib tedavisi uyumu açısından önemli olduğu için bu olguyu sunmaya karar verdik.
Anahtar sözcükler: Akneiform erüpsiyon, erlotinib, küçük hücreli dışı akciğer kanseri
References
- Schalock PC, Zug KA. Acneiform reaction to erlotinib. Dermatitis 2007; 18: 230
- Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
- Ong CK, Tan WC, Chan LC; Razak MA. Cutaneous Side-Effects of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (TKI) In the Treatment of Lung Cancer: Description and Its Management. Med J Malaysia 2012; 67: 222-3. Journagan S, Obadiah J. An acneiform eruption due to erlotinib: Prognostic implications and management. J Am Acad Dermatol 2006; 54: 358-60.
- Bovenschen HJ, Alkemade JA, Erlotinib-induced dermatologic side-effects. Int. J. Dermatol 2009; 48: 326-8.
- Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33.
- Hidalgo M, Siu LL, Nemunaitis J. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-79.
- Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric antiepidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002; 138: 129-31.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Case Reports |
| Authors | |
| Publication Date | February 14, 2014 |
| Published in Issue | Year 2013Volume 35, Issue 4 (2013): Supplement |